Qyuns Therapeutics Co., Ltd. (02509) disclosed a share repurchase on 25 November 2025. According to the announcement, the company repurchased 23,200 H shares on the Hong Kong Stock Exchange. The highest repurchase price was HKD 20.46, while the lowest price was HKD 20.2, with a total payment of approximately HKD 472,727.84. These repurchased shares are held as treasury shares.

Following this transaction, the number of issued shares (excluding treasury shares) decreased from 226,193,000 to 226,169,800, and treasury shares increased from 878,600 to 901,800. The total number of issued shares remained at 227,071,600. The repurchase accounted for around 0.0103% of the company’s previously issued shares (excluding treasury shares). The stated repurchase mandate was granted on 20 June 2025, with an authorized limit of 22,207,160 shares.